TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Analyze the Status of the Adoptive Cell Therapy Industry as of August 2016 - Research and Markets
Oct 18, 2016, 01:10 ET
DUBLIN, October 18, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016" report to their offering.
The report, "TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs" describes and analyzes the status of the adoptive cell therapy industry as of August 2016.
The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.
The report highlights and discusses
- Company financing;
- Business development & financing;
- Improvements of CAR T-cell therapy incl. gene editing and universal CARTs;
- Engineered TCR T-cells, including TCR target discovery;
- The current status of DLIs, CTLs and TILs;
- Manufacturing of T-cells for adoptive cell therapy;
- NK cells and CAR engineered NK cells;
- International perspective on TCR & CAR T-cell and NK cell therapy; and
- Key success factors & convergence of technologies.
The early and impressive clinical results of anti-CD19 CAR T-cell therapy most probably will see confirmation in ongoing pivotal studies in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) leading to approval as early as 2017.
Supported by Big Pharma money and billions of US$ by private financing rounds, public offerings and partnering money, Novartis, Juno Therapeutics and Kite Pharma are in a close race to be first on market with autologous CD19 CAR T-cell products. Cash-rich Juno and Kite went on a shopping and licensing tour to add numerous technologies like pearls on a string to be prepared for next generation development candidates.
However, clinical experience with CD19 CAR T-cells and other CAR T-cells for hematologic and solid tumors has revealed quite a number of hurdles.
Part of them have to be addressed by protocol issues, such as the pre-conditioning chemotherapy problem, or clinical combination studies with checkpoint inhibitors to modulate the tumor micro-environment. But technological solutions are far more required to improve safety and efficacy as well as convenience and manufacturing of CAR T-cell therapies. Another big issue is the lack of strictly tumor-specific targets.
Among the key technologies are gene editing and TCR target discovery. Companies with such capabilities will have a strong position in financing, partnering and corporate development. This report describes the key players in the field and companies with complementary technologies ideal for joint ventures, or better, mergers.
Who will benefit from this report?
- Technology Officers
- Corporate Development
- Strategic Planning
- Business Development & Licensing
- Corporate Finance
- Portfolio Management
- Investors & Analysts
- Clinical Development
- Research & Development
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Company Financing
4 Business Development & Licensing
5 Improvement of Chimeric Antigen Receptor (CAR) T-Cell Therapy
6 Competitive CAR T-Cell Pipeline Analysis
7 Engineered TCR T-Cells
8 Donor Lymphocyte Infusions (DLI)
9 Cytotoxic T-Lymphocytes (CTL)
10 Tumor Infiltrating Lymphocytes (TIL)
11 Manufacturing of T-Cells for Adoptive Cell Therapy
12 Natural Killer (NK) Cells
13 International Perspective on TCR & CAR T-Cell Therapy
14 Key Success Factors & Convergence of Technologies
15 Company Profiles
16 Cell Therapy Profiles
17 References
Companies Mentioned
- Adaptimmune
- Adicet Bio
- American Yuva Biomed
- Amgen
- Astellas Pharma
- Atara Biotherapeutics
- Aurora Biopharma
- Autolus
- Beijing Doing Biomedical
- Bellicum Pharmaceuticals
- BioNTech
- BioVec
- Bluebird bio
- CARSgen Therapeutics
- CPT - Cell Processing Therapy & GEMoab Monoclonals
- Catapult Therapy TCR
- Celgene
- Cell Medica
- Cellectis
- CellforCURE
- Cellular Biomedicine Group
- Cellular Therapeutics
- Celyad
- Chimeric Therapeutics
- CytomX Therapeutics
- EUFETS
- Eli Lilly
- Eureka Therapeutics
- Five Prime
- Formula Pharmaceuticals
- Gadeta
- GlaxoSmithKline
- Green Cross LabCell
- iCell Gene Therapeutics
- Immatics US
- Immune Therapeutics
- Innovative Cellular Therapeutics
- Intrexon
- JW Biotechnology
- Janssen
- Juno Therapeutics
- Kite Pharma
- Leucid Bio
- Lion Biotechnologies
- Lonza Wakersville
- MaSTherCell
- MaxCyte
- Medigene
- Merck KGaA
- Miltenyi Biotec
- MolMed
- Mustang Bio
- Nantkwest
- Nextera
- Novartis
- ONO Pharmaceutical Co
- Oxford BioMedica
- Persongen Biomedicine
- Pfizer
- Poseida Therapeutics
- Precision BioSciences
- Progenitor Cell Therapy (PCT)
- Regeneron Pharmaceuticals
- Seattle Genetics
- Servier
- Shanghai GeneChem
- Shenyang Sunshine Pharmaceutical
- Shire (Baxalta)
- Sinbioway Cell Therapy
- Sorrento Therapeutics
- TILT Biotherapeutics
- TNK Therapeutics
- Takara Bio
- The Cell and Gene Therapy Catapult
- Theravectys
- ThermoFisher
- Triumvira Immunologics
- Universal Cells
- Unum Therapeutics
- ViroMed
- Vor Biopharma
- WuXi AppTec
- ZIOPHARM Oncology
For more information about this report visit http://www.researchandmarkets.com/research/d5pmkm/tcr_and_car
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets